Other breast cancer targeted therapies include lapatinib and bevacizumab, as well as a number of drugs that have entered clinical studies but are not yet available.
Lapatinib is an oral epidermal growth factor receptor (HER-1, HER-2) small molecule tyrosine kinase inhibitor that remains effective after trastuzumab resistance in HER-2-positive breast cancer patients. Currently, it is mainly used for HER-2-positive advanced breast cancer, which is given capecitabine in combination with lapatinib after trastuzumab treatment has failed, or trastuzumab in combination with lapatinib regimen. Clinical studies on the application of lapatinib in postoperative adjuvant therapy for HER-2-positive breast cancer patients are ongoing and have not yet been concluded. Yan Min, Department of Breast Medicine, Henan Cancer Hospital
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) receptor, is currently recommended for recurrent or metastatic breast cancer, and paclitaxel is preferred in combination with bevacizumab. Clinical studies of bevacizumab for the adjuvant treatment of triple-negative breast cancer are ongoing.
Lapatinib and bevacizumab are currently not approved in China.